82
Participants
Start Date
January 22, 2020
Primary Completion Date
January 4, 2022
Study Completion Date
January 4, 2022
EDP-938
Four tablets daily for 5 days
Placebo
Four tablets daily for 5 days
Diagnostic and Consulting Center Aleksandrovska EOOD, Sofia
Medical Center Hera, Sofia
Multiprofile Hospital for Active Treatment Puls, Blagoevgrad
Lakeland Clinical Trials, Rotorua
City Outpatient Clinic #9, Kyiv
Medical Center of LLC Preventclinic, Kyiv
Lakeland Clinical Trials - Waikato, Hamilton
Medical Center Zdrave-1 OOD, Kozloduy
Limited Liability Company Medical Center Consilium Medical, Kyiv
Medical Center Tara OOD, Veliko Tarnovo
Specialized Hospital for Active Treatment of Pneumophthisiatric Diseases - Haskovo EOOD, Haskovo
Clinical Projects Research SA pty Ltd, Worcester
Progressive Medicine of the Triad, LLC, Winston-Salem
Carolina Research Center, Shelby
PMG Research of Wilmington, Wilmington
Miami Clinical Research - ClinEdge - PPDS, Miami
Cahaba Research Inc. - Birmingham, Pelham
Central Alabama Research, Birmingham
Municipal Enterprise The 1st City Clinical Hospital of Poltava City Council, Poltava
Pioneer Clinical Research LLC, Bellevue
Meridian Clinical Research, Norfolk
Communal Non-Profit Enterprise City Clinical Hospital #1 of Ivano-Frankivsk City Council, Ivano-Frankivsk
FMC Science, Lampasas
Clinical Research of South Nevada, Las Vegas
Torrance Clinical Research Institute, Lomita
Saint Joseph's Clinical Research, Anaheim
Instituto Medico Platense, Buenos Aires
Alergo-Med Specjalistyczna Przychodnia Lekarska Sp. z.o.o, Tarnów
Specjalistyczny Osrodek Leczniczo-Badawczy Zbigniew Zegota, Ostróda
Lead Sponsor
Collaborators (1)
PPD Development, LP
INDUSTRY
Enanta Pharmaceuticals, Inc
INDUSTRY